Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse
Recruiting now · Not applicable
Conditions studied: Leukemia, Lymphoblastic, Acute, Pediatric
In brief
B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.
Key facts
- Study ID
- NCT06649253
- Run by
- Rennes University Hospital
- People needed
- 50
- Starts
- 2025-03-22
- Expected to finish
- 2035-04-01
- Last updated by the study team
- 2026-01-02
Who can join
Age: any, up to 17. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Under 18 years
- With established diagnosis of B-ALL
- Initial diagnosis made in the investigating centre
- Having received oral and written information about the protocol, or oral only if the patient is unable to read.
- Having signed a consent form if the patient is capable of giving informed written consent.
- Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent.
- Beneficiary of a social security scheme
You may not qualify if…
- Isolated extramedullary involvement at inclusion
- Patient of childbearing age without effective contraception.
- Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.
Where it is running
- CHU Angers — Angers, France (enrolling)
- CHU Brest — Brest, France (enrolling)
- CHU Rennes — Rennes, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.